Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20150622022869N11
IRCT20150622022869N11
Recruiting
Phase 3

Comparison of the effect of OABM WITH OABF regimens in In the treatment of Helicobacter pylori patients

Yasouj University of Medical Sciences0 sites70 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Yasouj University of Medical Sciences
Enrollment
70
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Yasouj University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • •A patient who underwent endoscopy and has peptic ulcer disease (PUD).
  • •Patients with dyspepsia without endoscopic indication have a positive Helicobacter diagnostic test, including Helicobacter stool antigen test and....
  • •Patients with maltoma
  • •Endoscopy patients with nud (non\-ulcer dyspepsia) and patients with a history of cancer in their first degree relatives will be included in the study.
  • •Patients who have a history of pud and are Helicobacter positive and are taking NSAID
  • •Treatment\-resistant dyspepsia
  • •Patient satisfaction

Exclusion Criteria

  • •Previous history of H pylori treatment
  • •Allergy to antibiotics
  • •Allergy to PPI
  • •History of gastrectomy
  • •Having gastric cancer
  • •pregnant women
  • •Taking antibiotics in the last month
  • •Taking PPI or h2blocker in the last two weeks
  • •Chronic liver, kidney or lung disease
  • •History of Fauvism

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUS
EUCTR2005-002892-34-IEAstraZeneca SAS1,150
Active, not recruiting
Not Applicable
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSMen or women who are =18 years old diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS) and onset of clinical symptoms less than 48 hours at the admission for which a PCI is planned or anticipated. Patients with STEMI and primary PCI planned within 24 hours of admission will not be included. Patients will not be allowed to have taken any cholesterol-lowering medications during 1 month prior to enrolment.
EUCTR2005-002892-34-GRAstraZeneca SAS1,150
Active, not recruiting
Not Applicable
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSMen or women who are >18 and <75 years old diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS) and onset of clinical symptoms less than 24 hours at the admission for which a PCI is planned or anticipated. Patients with STEMI and primary PCI planned within 24 hours of admission will not be included. Patients will not be allowed to have taken any cholesterol-lowering medications during 1 month prior to enrolment.
EUCTR2005-002892-34-PTAstraZeneca SAS1,150
Active, not recruiting
Not Applicable
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSMen or women who are =18 years old diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS) and onset of clinical symptoms less than 48 hours at the admission for which a PCI is planned or anticipated. Patients with STEMI and primary PCI planned within 24 hours of admission will not be included. Patients will not be allowed to have taken any cholesterol-lowering medications during 1 month prior to enrolment.
EUCTR2005-002892-34-EEAstraZeneca SAS1,150
Active, not recruiting
Phase 1
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome.Comparación de los Efectos Observados en el cociente ApoB/ApoA-I, tras el Uso de Rosuvastatina y Atorvastatina en pacientes con Síndrome Coronario Agudo - CENTAURUS - CENTAURUSMen or women who are >18 and <75 years old diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS) and onset of clinical symptoms less than 24 hours at the admission for which a PCI is planned or anticipated. Patients with STEMI and primary PCI planned within 24 hours of admission will not be included. Patients will not be allowed to have taken any cholesterol-lowering medications during 1 month prior to enrolment.
EUCTR2005-002892-34-ESAstraZeneca SAS1,150